Occlutech is a leading specialist provider of minimally invasive cardiac devices, with a mission to improve the quality of life for people with heart conditions. The vision is to become a global leading specialist provider in cardiac devices, addressing congenital heart defects, stroke prevention and heart failure.
Since 2003, Occlutech has developed, manufactured, and commercialized occluders and interatrial shunt products. Occlutech has a broad and proven portfolio, based on proprietary technology, and over 200 patents with more than 150,000 products sold.
Occlutech markets and sells its structural heart and interatrial shunt products to hospitals and clinics in approximately 85 countries through its direct sales organization and international network of distribution partners.
Occlutech has around 275 employees and maintains manufacturing and R&D facilities in Jena, Germany and Istanbul, Turkey, with a global supply and customer support hub located in Helsingborg, Sweden.
Occlutech combines several base technologies and expertise to create state-of-the-art cardiac and vascular implants. Technologies have been developed and patented by Occlutech to make a difference and allow better treatment of patients around the world. Occlutech wants to be at the forefront of new technologies and our R&D teams spend a lot of time discussing new treatment options for current and new therapeutic areas in the rapidly developing structural heart disease area.